Special Issue "Recent Trends in Oligonucleotide Based Therapies"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 18040
Special Issue Editors
Interests: chemical-modified therapeutic oligonucleotides; antisense oligonucleotides; RNA interference; antiproliferative oligonucleotides; sequence-specific protein–DNA/RNA interactions; lipid- and polymer-based drug delivery systems; programmable self-assembling DNA nanostructures
2. Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain
Interests: antisense technology; bioconjugation; drug delivery; formulation; nucleic acids chemistry; nucleic acids delivery; polymeric nanoparticles; RNA interference
Special Issues, Collections and Topics in MDPI journals
2. Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain
Interests: siRNA; antisense oligonucleotides; G-quadruplex; DNA triplex; i-motif; DNA nanotechnology; gene silencing; aptamers; drug delivery; DNA; RNA; oligonucleotide synthesis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides, mainly antisense DNA and small interfering RNA, with several already hitting the market. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19 pandemic. These molecules have the power to tackle targets that are usually considered to be “undruggable” by blocking the translation or transcription of a specific gene by stimulating the degradation of a particular messenger RNA. So far, multiple technologies have been developed to enhance oligonucleotide pharmacokinetics and pharmacodynamics. The most commonly used strategies include chemical modification, conjugation to cell-targeting moieties, and nanoparticle formulation. However, despite all of the progress that has been made, their rapid degradation in biological fluids along with the difficulty of crossing physiological barriers make cell delivery a hard task to achieve, and there is still a need for more competent delivery approaches.
This Special Issue aims to collect reviews, original research articles, and short communications covering innovative strategies in the design, synthesis, and characterization of therapeutic oligonucleotides as well as advances in their delivery based on nanotechnologies. Research concerning the study of sequence-specific protein–DNA/RNA interactions will be also considered.
We are pleased to invite you to contribute your valuable research to this Special Issue on “Recent trends in oligonucleotide based therapies”.
Dr. Andreia F. Jorge
Prof. Dr. Ramon Eritja
Dr. Santiago Grijalvo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
• nanomedicine
• oligonucleotide delivery systems
• chemical-modified oligonucleotices
• oligonucleotide conjugates
• antisense oligonucleotides
• RNA interference
• anti-miRNA oligonucleotides
• aptamers
• protein–DNA/RNA interactions.